How to achieve end-organ protection: the potential of SGLT2 inhibitors (empagliflozin) not only in a new indication for the treatment of chronic kidney disease

Česká verzia

Authors: Zbynek Schroner
Authors place of work: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in the journal: Diab Obez 2024; 24(48): 121-123
Category: Reviews

Summary

By newest international and national guidelines, SGLT2 inhibitors are prefered choice in patients with type 2 diabetes mellitus in combination with metformin in all phases of cardiovascular continuum. Cardio-renal-metabolic benefits of this class of drugs confirmed clinical randomized studies and studies from real world evidence. By clinical studies are proven new therapeutic indications for SGLT2 inhibitors and also in Slovakia new enlarged indications limitations for this group of drugs. By early therapeutic intervention we can save lifes of our patients and also contribute before damaging of important organs as heart and kidney.

Keywords:

type 2 diabetes mellitus – empagliflozin – therapy – indications limitations

Zdroje

Martinka E, Tkáč I, Mokáň M et al. Odporúčané postupy pre liečbu diabetes mellitus 2. typu 2023. Forum Diab 2023; 12(2): 93–133.

Lacka J, Martinka E, Uličiansky V et al. Komplexný manažment diabetikov 2. typu. Štandardné postupy MZ SR. Diab Obez 2024; 24 (Suppl): S5-S58.

Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) 2022. Diabetes Care 2022; 45(11): 2753–2786. Dostupné z DOI: <http://dx.doi.org/10.2337/dci22–0034>.

Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(249): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.

Hiddo JL, Heerspink H, Bergur V et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.

Herrington WG, Staplin N, Wanner C et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388(2): 117–127. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2204233>.

Jardiance. Súhrn charakteristických vlastností lieku. ŠÚKL 2024. Dostupné z WWW: <https://www.sukl.sk>.

Melzer-Cohen C, Schechter M, Rozenberg A et al. Long-term real-world kidney out comes with SGLT2i versus DPP4i in type 2 diabetes without cardiovascular or kidney disease. Clin J Am Soc Nephrol 2023; 18(9): 1153–1162. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.0000000000000218>.